Ozempic-famed Novo Nordisk took over a $70 billion wipeout off its market value this week. Is this the beginning of a trend, ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

Eli Lilly (LLY) stock in focus as its diabetes drug Mounjaro causes heart benefits suceeding in a late-stage trial versus its ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type ...

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

We recently published 10 Stocks That Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim ...